No, that’s not a typo. I’m feeling optimistic about fundraising opportunities for small biotechs. Yes, I know we’re seeing venture firms pull back on an almost weekly basis (Prospect Ventures, Scale Venture Partners, etc.). And yes, I know the NVCA said VCs are fleeing life sciences. And yes, I know the initial public offering (IPO) window remains dubious at best.
BUT . . . there are some really interesting new options making their way through Congress, as anyone who read either BioWorld Insight or BioWorld Today on Monday already knows. For everyone else, here’s the low-down:
H.R. 1070 ‑ would provide an alternative to the IPO by letting private firms raise up to $50 million publicly and trade their shares, without the expense of becoming a reporting company (under current Regulation A rules, companies can only raise $5 million, which makes it hardly worth the trouble ‑ see more on that in BioWorld Insight next week)
To read the full, original article click on this link: An Optimist’s Take on Funding Options for Small Biotechs | BioWorld
